Table 2 Sensitivity of the DNN model for predicting colorectal cancer and lung cancer at a specificity of 99.2%.

From: Advances in methylation analysis of liquid biopsy in early cancer detection of colorectal and lung cancer

Healthy controls

   
 

N

Positive

Specificity (95% CI)

Total

126

1

99.2 (95.6–99.9)*

   

Clinical stage

Colorectal cancer

Lung cancer

Total N

Positive

Sensitivity (95% CI)

Total N

Positive

Sensitivity (95% CI)

All

96

75

78.1 (68.9–85.2)

95

63

66.3 (56.3–75.0)

I

17

13

76.5 (52.7–90.4)

32

16

50.0 (33.6–66.4)

II

21

16

76.2 (54.9–89.4%)

9

4

44.4 (18.9–73.3)

III

46

36

78.3 (64.4–87.7)

23

18

78.3 (58.1–90.3)

IV

12

10

83.3 (55.2–95.3)

31

25

80.6 (63.7–90.8)

I–II

38

29

76.3 (60.8–87.0)

41

20

48.8 (34.3–63.5)

  1. *Sensitivity for each cancer type was calculated based on the specificity of 99.2%, which allowed 1 false positive sample out of 126 healthy control samples.
Back to article page